Virginia Barchi

Virginia Barchi

Auto-generated profile, based on publicly available information

Virginia Barchi

Regional AIDS Reference Center, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Drug Safety
Verified
Journal Article
Closed access
PDF file
LRLorenzo Vittorio Rindi
Lorenzo Vittorio Rindi
DZDrieda Zace
Drieda Zace
NBNeva Braccialarghe
Neva Braccialarghe
BMBarbara Massa
Barbara Massa
VBVirginia Barchi
Virginia Barchi
Marco IannettaMarco Iannetta
Marco Iannetta

2 October 2025 in Eurosurveillance
Verified
Journal Article
Open access
DMDavide Moschese
Davide Moschese
RERozenn Esvan
Rozenn Esvan
CFChiara Fusetti
Chiara Fusetti
VBVirginia Barchi
Virginia Barchi
Maria Vittoria CossuMaria Vittoria Cossu
Maria Vittoria Cossu
valentina mazzottavalentina mazzotta
valentina mazzotta
Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.